Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial
In patients with varying degrees of kidney function, canagliflozin reduced cardiovascular and kidney outcomes, regardless of age, with no additional safety concerns identified in older patients.
Authors
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Carol A. Pollock (ORCID: https://orcid.org/0000-0001-7167-6495)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Clare Arnott (ORCID: https://orcid.org/0000-0001-9370-9913)
- Adeera Levin (ORCID: https://orcid.org/0000-0003-2438-8401)
- Luke Buizen
- Sradha S. Kotwal (ORCID: https://orcid.org/0000-0002-3294-4087)
- David M. Charytan (ORCID: https://orcid.org/0000-0002-7695-3583)
- Min Jun (ORCID: https://orcid.org/0000-0003-1460-7535)
- Amanda Siriwardana (ORCID: https://orcid.org/0000-0003-2417-8500)
- Meg Jardine (ORCID: https://orcid.org/0000-0002-0160-2375)
- Vlado Perkovic
Institutions
- The University of Sydney (AU)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University of Groningen (NL)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Concord Repatriation General Hospital (AU)
- UNSW Sydney (AU)
- Prince of Wales Hospital (AU)
- The George Institute for Global Health (AU)
- National Health and Medical Research Council (AU)
- New York University (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1111/dom.16190
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- Janssen Research and Development